Dyadic International (DYAI) Accumulated Expenses (2017 - 2026)
Dyadic International (DYAI) posted Accumulated Expenses of $891420.0 for Q1 2026, down 7.91% sequentially from $967974.0 in Q4 2025, and up 29.03% YoY from $690859.0 in Q1 2025.
Dyadic International (DYAI) Accumulated Expenses (2017 - 2026) Analysis & Trends
Dyadic International has reported Accumulated Expenses for 10 years, with the latest figure at $891420.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 29.03% year-over-year to $891420.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $891420.0 (up 29.03% YoY) and the FY2025 annual result came in at $967974.0, changed 0.26% from the prior year.
- Accumulated Expenses slipped to $891420.0 in Q1 2026 per DYAI's latest filing, from $967974.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $533.0 million in Q1 2022 and troughed at $309203.0 in Q2 2022.
- A 5-year average of $32.1 million and a median of $891420.0 in 2026 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 304110.38% in 2022, then slumped 99.84% in 2023.
- Over 5 years, Accumulated Expenses stood at $580264.0 in 2022, then dropped by 3.2% to $561720.0 in 2023, then soared by 72.77% to $970462.0 in 2024, then dropped by 0.26% to $967974.0 in 2025, then dropped by 7.91% to $891420.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $891420.0, $967974.0, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 891,420.00 |
| Dec 31, 2025 | 967,974.00 |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 929,850.00 |
| Mar 31, 2025 | 690,859.00 |
| Dec 31, 2024 | 970,462.00 |
| Sep 30, 2024 | 442,604.00 |
| Jun 30, 2024 | 870,597.00 |
| Mar 31, 2024 | 987,973.00 |
| Dec 31, 2023 | 561,720.00 |
| Sep 30, 2023 | 429,820.00 |
| Jun 30, 2023 | 909,482.00 |
| Mar 31, 2023 | 863,041.00 |
| Dec 31, 2022 | 580,264.00 |
| Sep 30, 2022 | 987,891.00 |
| Jun 30, 2022 | 309,203.00 |
| Mar 31, 2022 | 533.01 Mn |
| Dec 31, 2021 | 405,758.00 |
| Sep 30, 2021 | 410,780.00 |
| Jun 30, 2021 | 276,112.00 |